World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
75
Citations
28205
World Ranking
19000
National Ranking
9471

Pierre P. Massion publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Pierre P. Massion sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 391 publications — 37th percentile

37% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Pierre P. Massion D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Pierre P. Massion sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 75 D-Index — 6th percentile

6% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2015 - Fellow of the American Association for the Advancement of Science (AAAS)

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Gene
  • Internal medicine

His main research concerns Lung cancer, Cancer research, Pathology, Cancer and Lung. His research integrates issues of Carcinogenesis and Cohort in his study of Lung cancer. His Cancer research study incorporates themes from Mutation, Gene mutation, Signal transduction, Exon and Rovalpituzumab tesirine.

His Pathology study integrates concerns from other disciplines, such as Biomarker, Proteomics and Adenocarcinoma. His Cancer research incorporates elements of Survival rate, Carcinoma, Immunology and Hazard ratio. His Lung research is multidisciplinary, incorporating elements of Frozen section procedure and Receiver operating characteristic.

His most cited work include:

  • ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers (1094 citations)
  • Comprehensive genomic profiles of small cell lung cancer (866 citations)
  • The national lung screening trial: Overview and study design (715 citations)

What are the main themes of his work throughout his whole career to date?

Pierre P. Massion mostly deals with Lung cancer, Cancer research, Internal medicine, Cancer and Pathology. His research in Lung cancer intersects with topics in Biomarker, Radiology, Lung and Early detection. His research integrates issues of Non small cell, Small Cell Lung Carcinoma, Cell growth, Metastasis and Adenocarcinoma in his study of Cancer research.

Pierre P. Massion has included themes like Gastroenterology, Endocrinology and Oncology in his Internal medicine study. His research investigates the connection with Cancer and areas like Immunology which intersect with concerns in COPD. His research in Pathology tackles topics such as Proteomics which are related to areas like Bioinformatics.

He most often published in these fields:

  • Lung cancer (76.56%)
  • Cancer research (30.99%)
  • Internal medicine (27.60%)

What were the highlights of his more recent work (between 2018-2021)?

  • Lung cancer (76.56%)
  • Cancer research (30.99%)
  • Lung (25.26%)

In recent papers he was focusing on the following fields of study:

Lung cancer, Cancer research, Lung, Internal medicine and Lung cancer screening are his primary areas of study. His work carried out in the field of Lung cancer brings together such families of science as Retrospective cohort study, Emergency medicine, Confidence interval, Radiology and Tumor progression. The concepts of his Cancer research study are interwoven with issues in Cell growth, Autoantibody, Small hairpin RNA, Non small cell and Adenocarcinoma.

In his research on the topic of Lung, Computed tomographic, Prostate, Noninvasive biomarkers and Diagnostic biomarker is strongly related with Nodule. His Internal medicine study combines topics in areas such as Gastroenterology and Oncology. Pierre P. Massion studied Cohort and Cancer that intersect with CD8.

Between 2018 and 2021, his most popular works were:

  • Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. (169 citations)
  • Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges (77 citations)
  • The Human Tumor Atlas Network: Charting Tumor Transitions Across Space and Time at Single-Cell Resolution (65 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Gene
  • Internal medicine

His scientific interests lie mostly in Lung cancer, Lung, Internal medicine, Cancer research and Lung cancer screening. His Lung cancer study incorporates themes from Retrospective cohort study, Confidence interval, Tumor progression, Qualitative feedback and Receiver operating characteristic. His Lung research is multidisciplinary, incorporating perspectives in Normal results, Curative treatment and Emergency medicine.

Pierre P. Massion works mostly in the field of Internal medicine, limiting it down to topics relating to Oncology and, in certain cases, Human genetics and Non invasive. His Cancer research research includes elements of Cell growth, NEUROD1, ASCL1, Small hairpin RNA and Genetically Engineered Mouse. The various areas that Pierre P. Massion examines in his Lung cancer screening study include Odds ratio, Guideline and Family medicine.

Best Publications

  • Comprehensive genomic profiles of small cell lung cancer

    Julie George;Jing Shan Lim;Se Jin Jang;Yupeng Cun

  • ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

    Kristin Bergethon;Alice T. Shaw;Sai Hong Ignatius Ou;Ryohei Katayama

  • The national lung screening trial: Overview and study design

    Constantine A. Gatsonis;Denise R. Aberle;Christine D. Berg;William C. Black

  • Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data.

    Charles M. Rudin;John T. Poirier;Lauren Averett Byers;Caroline Dive

  • Proteomic patterns of tumour subsets in non-small-cell lung cancer.

    Kiyoshi Yanagisawa;Yu Shyr;Baogang J Xu;Pierre P Massion

  • The Human Tumor Atlas Network: Charting Tumor Transitions Across Space and Time at Single-Cell Resolution

    Orit Rozenblatt-Rosen;Aviv Regev;Aviv Regev;Aviv Regev;Philipp Oberdoerffer;Tal Nawy

  • A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo

    Laura R. Saunders;Alexander J. Bankovich;Wade C. Anderson;Monette A. Aujay

  • Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.

    Douglas E. Wood;Ella A. Kazerooni;Scott L. Baum;Georgie A Eapen

  • Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer

    Joseph Amann;Shailaja Kalyankrishna;Pierre P. Massion;Joyce E. Ohm

  • Integrating genomic features for non-invasive early lung cancer detection

    Jacob J. Chabon;Emily G. Hamilton;David M. Kurtz;Mohammad S. Esfahani

  • Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma.

    Nicholas J. Wang;Zachary Sanborn;Kelly L. Arnett;Laura J. Bayston

  • Mass Spectrometry to Classify Non–Small-Cell Lung Cancer Patients for Clinical Outcome After Treatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Multicohort Cross-Institutional Study

    Fumiko Taguchi;Benjamin Solomon;Vanesa Gregorc;Heinrich Roder

  • Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis

    Eric E. Gardner;Eric E. Gardner;Benjamin H. Lok;Valentina E. Schneeberger;Patrice Desmeules

  • Tumour angiogenesis regulation by the miR-200 family

    Chad V. Pecot;Rajesha Rupaimoole;Da Yang;Rehan Akbani

  • Significance of p63 amplification and overexpression in lung cancer development and prognosis.

    Pierre P. Massion;Peter M. Taflan;S. M. Jamshedur Rahman;Pinar Yildiz

  • Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges

    Luis M. Seijo;Nir Peled;Daniel Ajona;Mattia Boeri

  • High-throughput proteomic analysis of formalin-fixed paraffin-embedded tissue microarrays using MALDI imaging mass spectrometry.

    M. Reid Groseclose;Pierre P. Massion;Pierre P. Massion;Pierre Chaurand;Pierre Chaurand;Richard M. Caprioli;Richard M. Caprioli

  • SLC1A5 Mediates Glutamine Transport Required for Lung Cancer Cell Growth and Survival

    Mohamed Hassanein;Megan D. Hoeksema;Masakazu Shiota;Jun Qian

  • Airway PI3K Pathway Activation Is an Early and Reversible Event in Lung Cancer Development

    Adam M. Gustafson;Raffaella Soldi;Christina Anderlind;Mary Beth Scholand

  • Genomic Copy Number Analysis of Non-small Cell Lung Cancer Using Array Comparative Genomic Hybridization Implications of the Phosphatidylinositol 3-Kinase Pathway

    Pierre P. Massion;Wen-Lin Kuo;David Stokoe;Adam B. Olshen

Frequent Co-Authors

David P. Carbone
David P. Carbone The Ohio State University
Yu Shyr
Yu Shyr Vanderbilt University Medical Center
Bennett A. Landman
Bennett A. Landman Vanderbilt University
Yuankai Huo
Yuankai Huo Vanderbilt University
Timothy S. Blackwell
Timothy S. Blackwell University of Michigan–Ann Arbor
Joe B. Putnam
Joe B. Putnam The University of Texas MD Anderson Cancer Center
Robert S. Dittus
Robert S. Dittus Vanderbilt University Medical Center
Bo Lu
Bo Lu The Ohio State University
Richard M. Caprioli
Richard M. Caprioli Vanderbilt University
Avrum Spira
Avrum Spira Boston University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Medicine in the USA opens doors to various career paths beyond becoming a physician. Many students and professionals consider related fields that are accessible through flexible online education options. These programs can help you advance your career or pivot into high-demand healthcare roles.

If you’re interested in healthcare leadership, consider enrolling in the cheapest online master degree in healthcare administration. This degree can prepare you for administrative and management roles in hospitals, clinics, and healthcare organizations.

For nurses aiming to reach the highest practice levels, reviewing the cheapest dnp options online is a practical way to advance clinical expertise and leadership skills.

Pharmacists are vital members of the healthcare team, and aspiring professionals can explore online pharmacy schools for convenient and affordable pathways to a Pharm.D.

As technology transforms healthcare, data management is increasingly important. Earning a health information management degree online can lead to impactful roles organizing and securing health data.

Each of these degree paths offers excellent opportunities for career growth and specialization in the dynamic healthcare field.

Best Scientists Citing Pierre P. Massion

Recently Published Articles